^
    Back
    Association details:
    Biomarker:KRAS mutation
    Cancer:Lung Cancer
    Drug:erlotinib (EGFR inhibitor) +
    selisistat (SEN-196) (SIRT1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Exp Mol Med
    Title:

    Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer

    Published date:
    10/02/2023
    Excerpt:
    To confirm the in vivo benefits of SIRT1 inhibitor and/or erlotinib treatment endowed by KRASMut, H358 cells were inoculated via intratracheal injection....The combination treatment of EX527 and erlotinib resulted in a longer median survival time than that in either single treatment group or the untreated group...
    DOI:
    https://doi.org/10.1038/s12276-023-01091-0